Clinical studies of the vaccine regimen — which includes two components, a prime and a boost — first began in the United States and the United Kingdom in January. The second phase of the study began in July.
Valued at approximately $28.5 million, HHS says the agreement will “includes process optimization, characterization and validation of manufacturing processes; stability studies; fill-finish manufacturing; technology transfer between the two companies and related activities.”
The agreement has the option of being extended for up to seven years total and $69 million.
More articles on Ebola:
Physicians overestimate ability to assess patients’ Ebola risk, survey finds
Panel cites Epic EHR ‘challenges’ as contributing to Ebola misdiagnosis at Texas hospital
WHO declares Liberia Ebola-free
